WeightWatchers Soars on New Compounded GLP-1 Offering (1)

WeightWatchers shares jump as much as 34%, the most intraday since August, after saying its adding compounded semaglutide to its weight management program as part of a new offering starting at $129.

• “We do not view compounding as a durable business model longer term,” Barclays analyst Stephanie Davis writes, reiterating her underperform rating
  • Says the move to add compounded GLP-1 drugs “extends the cash runway for WW” and notes similar moves helped peers including for Hims & Hers Health have driven “a growth acceleration”
• The WeightWatchers move shows “significant demand is still present for branded and compounded GLP-1 drugs,” B ...